Biocat Report shows growth in international investment in BioRegion of Catalonia Blog Post

More than 300 professionals from the sector attended the event to present a new edition of the Biocat Report, the benchmark study on the healthcare and life sciences sector in Catalonia. Under de title “Escaling-up the BioRegion of Catalonia”, the Biocat Report highlights the growing attractiveness of the life sciences and health sector for international investment –linked to the positioning of the BioRegion as a European hub in health research–, the increase in the number of companies and the occupation of sector, as well as the advance of innovation in health towards social impact. Biocat, the organization that coordinates and promotes the life sciences sector in Catalonia, has its headquarters in the Barcelona Science Park.

 

AELIX Therapeutics and Gilead Sciences enter into a clinical research collaboration agreement for HIV Cure Blog Post

AELIX Therapeutics, a clinical-stage biotechnology company based in the Barcelona Science Park and specialized in the discovery and development of immunotherapies for HIV infection, announces that it has entered into a clinical research collaboration with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Both companies will jointly evaluatejointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

 

Researchers design a nano-carrier to release drugs into damaged cells Blog Post

A team headed by the ICREA researcher Manuel Serrano at the Institute for Research in Biomedicine (IRB Barcelona), located in the Barcelona Science Park (PCB), has designed a drug encapsulation system that selectively targets senescent cells. The study, published in EMBO Molecular Medicine, paves the way for therapeutic approaches to eliminate these zombi cells in many diseases, such as pulmonary fibrosis and cancer. This is currently a central goal for many pharmaceutical companies, among them the one co-founded by Manuel Serrano himself Senolytic Therapeutics, based in PCB and in Boston.

 

ICCUB becomes a Scientifica International technological partner Blog Post

The Institute of Cosmos Sciences (ICCUB) of the University of Barcelona has signed an agreement with the company Scientifica International to work together in the fields of nuclear and particle physics, space sciences and industry. One of the first licensed products for its trade is the Multi-purpose Integrated Circuit (eMUSIC), carried out at the ICCUB technology Unit (ICCUB-TECH), based in the Barcelona Science Park.

 

DTI Foundation: A decade promoting research and training in donation and transplant Blog Post

Yesterday, DTI Foundation (Donation &Transplantation Institute) celebrated its 10th anniversary at Barcelona Science Park. The Foundation —created in Barcelona in 2008— was conceived with the aim of providing consultancy, training and support to professionals from public and private organisations in creating, developing and strengthening networks, programmes and services in the area of organ, tissue and human cell donation and transplantation worldwide. Since its formation, the organization has trained over 14,000 healthcare professionals in the area of organ and tissue donation and transplantation in over 100 countries worldwide. 

 

EIT Health Wild Card: €4 million in search of innovative health ideas Blog Post

Under the new Wild Card programme, EIT Health consortium –the largest European body for innovation in healthy living and active ageing– has announced €4 million in funding for disruptive initiatives that help transform European healthcare and mitigate the social and economic impact of the progressive ageing of the population. The Universitat de Barcelona (UB), a core partner and promoter of EIT Health Spain, is one of the 14 European institutions that will offer advisory and incubation services to the two winning teams to turn their ideas into a business plan through of the Barcelona Entrepreneurship Institute (BIE), the Bosch i Gimpera Foundation (FBG) and the Barcelona Science Park (PCB). On Monday, January 29, an informative session will take place at the PCB.

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).

 

A team of UB and PCB takes part in the licence of a new technology of fluorescent dyes of biomedical interest Blog Post

A new article published in the journal Nature Protocols describes the new technology to develop a series of activable fluorophores that enable the peptide molecular labelling and improve cell-live imaging. The new study has the participation of the teams led by Rodolfo Lavilla, from the Faculty of Pharmacy and Food Sciences of the University of Barcelona and the Barcelona Science Park (PCB), and Marc Vendrell, from the Edinburgh Medical School (Scotland).